Recently, Beijing Hejing Biotechnology Co., Ltd. and its subsidiaries have obtained a number of qualifications. Including 5 domestic medical device registration certificates, all of which are Jiagong testing products, overcoming the bottleneck of the core raw material of the small molecule sandwich method, with better detection performance; 1 patent for “a gastric cancer diagnostic marker based on extracellular vesicle miRNA and its application”; and 1 “Liver Cancer Risk Analysis Software 1.0” computer software copyright. These qualifications enrich the company's product range, improve business areas and intellectual property systems, and enhance competitiveness. However, product sales are affected by various factors, and there is uncertainty.

Recently, Beijing Hejing Biotechnology Co., Ltd. and its subsidiaries have obtained a number of qualifications. Including 5 domestic medical device registration certificates, all of which are Jiagong testing products, overcoming the bottleneck of the core raw material of the small molecule sandwich method, with better detection performance; 1 patent for “a gastric cancer diagnostic marker based on extracellular vesicle miRNA and its application”; and 1 “Liver Cancer Risk Analysis Software 1.0” computer software copyright. These qualifications enrich the company's product range, improve business areas and intellectual property systems, and enhance competitiveness. However, product sales are affected by various factors, and there is uncertainty.